Efficacy and Safety of Etanercept 50 mg Once Weekly Plus As Needed Topical Agent in Moderate to Severe Plaque Psoriasis

PHASE3CompletedINTERVENTIONAL
Enrollment

310

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

December 31, 2012

Study Completion Date

May 31, 2013

Conditions
Psoriasis
Interventions
BIOLOGICAL

etanercept

Administered by subcutaneous injection

DRUG

Topical agents

"Topical agents prescribed at the discretion of the Principal Investigator and were are limited to the following:~* hydrocortisone 2.5%~* betamethasone valerate 0.1%~* betamethasone dipropionate 0.05%~* clobetasol 0.05%~* calcitriol~* calcipotriol plus betamethsone dipropionate 0.05%"

Trial Locations (24)

T2G 1B1

Research Site, Calgary

V3R 6A7

Research Site, Surrey

V5Z 4E8

Research Site, Vancouver

R3C 0N2

Research Site, Winnipeg

E1C 8X3

Research Site, Moncton

A1A 5E8

Research Site, St. John's

A1C 2H5

Research Site, St. John's

B3H 1Z4

Research Site, Halifax

L1E 3C3

Research Site, Courtice

P3C 1X8

Research Site, Greater Sudbury

L3P 1A8

Research Site, Markham

L5H 1G9

Research Site, Mississauga

P1B 3Z7

Research Site, North Bay

K9J 1Z2

Research Site, Peterborough

L4B 1A5

Research Site, Richmond Hill

M3H 5Y8

Research Site, Toronto

M4V 1R1

Research Site, Toronto

N2J 1C4

Research Site, Waterloo

N8W 5L7

Research Site, Windsor

H2K 4L5

Research Site, Montreal

H3Z 2S6

Research Site, Montreal

G1J 1X7

Research Site, Québec

G1V 4X7

Research Site, Québec

J2S 6L6

Research Site, Saint-Hyacinthe

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY